Recent studies have suggested that the most common and lethal type of 'ovarian' cancer, i.e. high-grade serous carcinoma (HGSC), usually arises from epithelium on the fallopian tube fimbriae, and not from the ovarian surface epithelium. We have developed Ovgp1-iCreER T2 mice in which the Ovgp1 promoter controls expression of tamoxifen-regulated Cre recombinase in oviductal epithelium -the murine equivalent of human fallopian tube epithelium (FTE). We employed Ovgp1-iCreER T2 mice to show that FTE-specific inactivation of several different combinations of tumour suppressor genes that are recurrently mutated in human HGSCs -namely Brca1, Trp53, Rb1, and Nf1 -results in serous tubal intraepithelial carcinomas (STICs) that progress to HGSC or carcinosarcoma, and to widespread metastatic disease in a subset of mice. The cancer phenotype is highly penetrant and more rapid in mice carrying engineered alleles of all four tumour suppressor genes. Brca1, Trp53 and Pten inactivation in the oviduct also results in STICs and HGSCs, and is associated with diffuse epithelial hyperplasia and mucinous metaplasia, which are not observed in mice with intact Pten. Oviductal tumours arise earlier in these mice than in those with Brca1, Trp53, Rb1 and Nf1 inactivation. Tumour initiation and/or progression in mice lacking conditional Pten alleles probably require the acquisition of additional defects, a notion supported by our identification of loss of the wild-type Rb1 allele in the tumours of mice carrying only one floxed Rb1 allele. Collectively, the models closely recapitulate the heterogeneity and histological, genetic and biological features of human HGSC. These models should prove useful for studying the pathobiology and genetics of HGSC in vivo, and for testing new approaches for prevention, early detection, and treatment.
Introduction
High-grade serous carcinoma (HGSC) is the most common and lethal type of 'ovarian' cancer, accounting for ∼70-75% of cases [1] . Recent studies have suggested that HGSCs usually arise in the fallopian tube epithelium (FTE), rather than in the ovarian surface epithelium (OSE) [2, 3] . HGSCs show a high level of chromosomal instability, and almost all of them harbour somatic TP53 mutations, which occur very early in HGSC pathogenesis, as TP53 mutations are also present in HGSC precursors, known as serous tubal intraepithelial carcinomas (STICs) [4] [5] [6] . Although only nine genes were shown to be significantly mutated in HGSCs by the Cancer Genome Atlas project [7] , somatic structural alterations (e.g. DNA copy number alterations, gene breakage, and gene fusions) are frequently seen in these tumours [7, 8] . These mutational and structural changes often lead to dysfunction of the RB, BRCA, phosphoinositide 3-kinase (PI3K) and RAS pathways. Genetic instability in the early lesions presumably contributes to the likelihood that somatic mutations conferring metastatic potential will be acquired. Thus, women with HGSCs typically have small primary lesions and widespread metastases at diagnosis. Ovarian carcinosarcomas [also known as malignant mixed Müllerian tumours (MMMTs)] show both malignant epithelial and mesenchymal elements, and are now thought to represent a much less common variant of HGSC [9] . Like HGSCs, pelvic/ovarian carcinosarcomas have been associated with STICs, and a recent study showed identical TP53 mutations in matched pairs of STICs and carcinosarcomas, providing evidence for their clonal relationship and the potential origin of carcinosarcoma in the fallopian tube [10, 11] .
Genetically engineered mouse models (GEMMs) of ovarian cancer that closely recapitulate their human tumour counterparts provide excellent in vivo systems with which to study tumour biology, and to perform preclinical studies aimed at improving ovarian cancer prevention, early detection, and therapy [12] . Historically, most HGSC GEMMs were based on OSE transformation [13] [14] [15] [16] . More recently, models based on transformation of oviduct (equivalent to human fallopian tube) epithelium (hereafter referred to as FTE) have been reported. Kim et al. developed an oviductal HGSC model based on conditional deletion of Dicer and Pten, using the Amhr2 promoter to express Cre recombinase in the murine oviduct [17] . The tumours in this model arise first in the fallopian tube stroma and are initially mesenchymal. More recently, Perets et al. described an HGSC GEMM, using the Pax8 promoter to drive Cre-mediated recombination of floxed Brca1 or Brca2, Pten and Trp53 alleles in the FTE of Pax8-rtTA;TetO-Cre mice [18] . Although these oviductal HGSC models represent a significant advance, both direct Cre expression by using gene promoters that lack specificity for the FTE. Amhr2 is also expressed in the OSE and stromal cells in the ovary, oviduct, and other portions of the female genital tract [19] , whereas Pax8 is expressed in other Müllerian epithelia, such as endometrial glandular epithelium, as well as other sites such as the kidney and thyroid [20] . A promoter for directing Cre expression to the FTE with greater specificity was highlighted by Miyoshi et al., who reported the development of oviductal HGSC-like tumours in mice expressing SV40-LTag under control of a 2.2-kb fragment of the murine Ovgp1 (oviductal glycoprotein 1) promoter [21] . We have developed mice in which the Ovgp1 promoter directs expression of tamoxifen (TAM)-regulated Cre recombinase in the FTE [22] . Ovgp1-iCreER T2 mice carrying floxed alleles of the Apc and Pten tumour suppressor genes (TSGs) invariably develop endometrioid-like tumours in the FTE following treatment with TAM, and these tumours are more similar to human ovarian endometrioid carcinomas in their morphology, biological behaviour and gene expression profiles than tumours based on Apc and Pten inactivation in the OSE [22] . Whereas our earlier work showed that the cell of origin has a profound impact on the tumour phenotype, in the present study we wished to test the hypothesis that genetics also affect the tumour phenotype. Given that dysregulation of Wnt and PI3K-AKT signalling -which is characteristic of human endometrioid carcinomas -in the oviductal epithelium results in mouse tumours with endometrioid-like morphology, we wanted to test whether inactivation of TSGs that are often mutated in human HGSCs (Brca1, Trp53, Rb1, and Nf1) [7] leads to HGSC-like tumours in the mouse oviduct. To build on the work of Perets et al., we also wished to test the effects of Brca1, Trp53 and Pten inactivation in our model system [18] . Although somatic PTEN point mutations are relatively uncommon in HGSCs, dysregulation of the PI3K-AKT signalling pathway is frequently observed, often as a consequence of PTEN gene breakage events or PIK3CA amplification [7, 8] .
Materials and methods

Genetically modified mice and animal care
The development and characterization of Ovgp1-iCreER T2 transgenic mice have been described in detail [22] 
In vivo induction of oviductal tumours
Ovgp1-iCre-ER T2 female mice carrying various engineered TSG alleles were given intraperitoneal injections of TAM (T5648; Sigma-Aldrich, Indianapolis, IN, USA) at 100 mg/kg body weight on three consecutive days, usually when mice were aged 6-8 weeks. Initially, while mice were monitored for tumour development, selected mice were killed at various time points following TAM injection and inspected for tumour location and extent at necropsy. Thirteen mice underwent survival surgery, during which the right oviduct and ovary were removed at 2 months (n = 11), 3 months (n = 1) or 12 months (n = 1) after TAM injection, and the mice were then monitored for tumour development in the remaining oviduct. Once the presence of a tumour had been established, most mice were monitored to humane endpoints. Mice were grossly evaluated for tumour extent, and, in each case, ovaries, oviducts, uteri, lungs, multiple abdominal organs, omentum and mesentery were examined microscopically.
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Histopathology and immunohistochemistry
Tissues were fixed in 10% buffered formalin and paraffin-embedded. Sections (5 μm) were haematoxylin and eosin (H&E)-stained for evaluation by light microscopy. To identify microscopic oviductal lesions, each oviduct and ovary were serially sectioned in their entirety for microscopic examination. Alternate sections were either stained with H&E or retained for immunohistochemical (IHC) staining, performed according to standard methods as previously described [22] . Antigen retrieval was performed by microwaving the slides in citrate buffer, pH 6.0 (Biogenex, San Ramon, CA, USA) for 15 min. Antigen-antibody complexes were detected with the avidin-biotin peroxidase method, with diaminobenzidine as the chromogenic substrate (Vectastain ABC kit; Vector Laboratories, Burlingame, CA, USA). The primary antibodies used were: rat anti-cytokeratin (CK) 8 (Developmental Studies Hybridoma Bank, University of Iowa), rabbit anti-p53 and rabbit anti-PAX8 (Proteintech, Chicago, IL, USA), rat anti-Ki67 (Dako, Carpinteria, CA, USA), and goat anti-OVGP1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Table S2 ). Mice with conditionally modified Brca1, Trp53 and Rb1 alleles are hereafter referred to collectively as BPR mice (n = 29). BPN mice (n = 3) are those with modified Brca1, Trp53 and Nf1 alleles, whereas BPRN mice (n = 48) carry modified alleles for all four TSGs. Data summarizing the oviductal lesions developing in these mice are shown in Figure 1 , in which mice with generally similar genotypes are grouped together.
Results
STICs
In order to determine whether Brca1, Trp53, Rb1 and/or Nf1 inactivation in the FTE results in an oviductal tumour phenotype, 10 mice with a range of defined genotypes were killed 1.5-6.5 months after TAM injection. One BPRN mouse (no. 2820) showed a microscopic lesion closely resembling human STIC in one oviduct 2.5 months after TAM injection. Oviductal lesions were not identified in the remaining nine mice. In an attempt to reduce the number of mice needed to determine whether, and how often, mice with different genotypes acquire oviductal tumours, the right oviduct and ovary were removed from 13 mice in a survival surgery procedure. Eleven of the 13 (four BPRN, six BPR, and one BPN) had the right oviduct and ovary removed 2 months after TAM injection. STIC was found in one BPRN mouse (no. 3867, with homozygous floxed alleles for all four TSGs). Two additional BPRN mice underwent survival surgery at 3 and 12 months after TAM injection (no. 3559 and no. 8234), and STIC was identified in the latter. Photomicrographs of two representative mouse STIC lesions are shown in Figure 2 . Like STICs in humans, mouse STICs have a predilection for arising in the distal portion of the oviduct (Figure 2A , C, equivalent to human fallopian tube fimbriae). The lesional cells show enlarged, hyperchromatic and pleomorphic nuclei, prominent nucleoli, increased mitotic activity, and loss of polarization ( Figure 2B, D) .
All 13 mice that underwent survival surgery were monitored for tumour development in the remaining oviduct for 5-23 months following TAM injection. Lesions were identified in the remaining oviduct in five of six BPRN mice, in two of six BPR mice, and in the BPN mouse. The oviductal lesions identified in the remaining oviduct included two STICs, two early HGSCs (confined to the oviduct), two HGSCs extending beyond the oviduct, and two MMMTs, one of which metastasized widely.
Oviductal lesions (STIC, early HGSC, HGSC, and/or MMMT) were identified in 50 of 57 additional mice (12 BPR, 36 BPRN and two BPN mice) not included in the groups described above. These mice were monitored for tumour development for time periods ranging from 7 to 24 months after TAM injection (Figure 1 ). In the 59 of 80 mice with oviductal lesions, tumour involved one or both ovaries in 24 (41%), obliterating the ovary in all but four cases. Widespread peritoneal metastases were observed in eight mice (14%) and ascites in seven mice (12%). In similar fashion to the human disease, metastases were often observed in the omentum. Representative photomicrographs showing tumour progression from STIC to early HGSC, HGSC/MMMT and metastatic disease are shown in Figure 3 , and IHC staining of primary tumours at various stages of tumour progression, and metastases to omentum and ovary, are shown in Figure 4 and supplementary material, Figure S1 , respectively. The tumour cells expressed CK8 and PAX8, and showed increased proliferation, based on IHC staining for Ki67. Tumours with the conditional Trp53 R172H mutant allele only occasionally showed focal stabilization of p53 (Figure 4 ; no. 3724). Whereas the neoplastic cells in STICs and HGSCs retain expression of PAX8, a marker of secretory cells, they do not express tubulin, which marks ciliated cells (supplementary material, Figure S2 ). The absence of tubulin expression is not surprising, as human HGSCs and STICs do not typically show ciliated morphology.
Only six of 48 (12.5%) BPRN mice, as compared with 15 of 29 (52%) BPR mice, failed to develop lesions. Some of the failures were probably attributable to mice being killed at relatively early time points (≤6.5 months after TAM injection), particularly in the BPR mice. All three BPN mice included in the study developed oviductal HGSC and/or MMMT. On a per oviduct basis, and excluding those removed at the time of survival surgery or evaluated earlier than 7 months after TAM injection, 87 oviducts had at least one floxed Nf1 allele. In these oviducts, 11% had no neoplastic lesions, 21% had STIC, 25% had early HGSC, and 43% had HGSC/MMMT. In contrast, for the 39 oviducts without floxed Nf1, the percentages were 36%, 41%, 13%, and 10%, respectively (P = 3.8 × 10 -5 , chi-squared test; P = 2.7 × 10 -6 , Mantel-Haenszel chi-squared test of association). On the basis of our analysis of the data shown in Figure 1 and in supplementary material, Table S2 , we conclude that the HGSC phenotype in our model is highly penetrant in BPRN and BPN mice, especially those carrying homozygous floxed alleles for all TSGs. Furthermore, disease progression is generally more rapid in BPRN than in BPR or BPN mice.
Cre-mediated recombination of Brca1, Trp53, Rb1 and Nf1 alleles in representative tumours was confirmed by PCR (supplementary material, Figure S3 ). Interestingly, in mice carrying one floxed and one wild-type Rb1 allele, loss of the wild-type Rb1 allele was seen in seven of eight tumours analysed (e.g. supplementary material, Figure S3 , nos. 13085, 13576, 13179, and 2117). Hence, as in human HGSC pathogenesis, the mouse tumours acquire additional genetic alterations during tumour progression. We evaluated oviductal tumour DNA for activation of the conditional Trp53 mutant allele in three representative tumours, two of which are shown in supplementary material, Figure  S3C . In all three tumours, recombination of the conditional mutant Trp53 allele was not observed. Interestingly, of mice with both oviducts intact for ≥7 months, three of six with the Trp53 LSL-R172H/+ genotype had no detectable oviductal lesions, whereas only four of 51 mice with at least one floxed Trp53 allele lacked lesions (P = 0.020, two-sided Fisher's exact test). These findings suggest that in this HGSC model system: (1) there is selection for biallelic inactivation of Rb1; and (2) the Trp53 fl allele, generating a null Trp53 mutation via Cre recombination, is preferable to the Trp53 LSL-R172H mutant allele, perhaps because of inefficient Cre recombination or the absence of selective pressure for recombination and/or selection against recombination. It is of note that, in the absence of Cre-mediated activation of the R172H mutation, the Trp53 LSL-R172H allele is null [23] .
In addition to the oviductal tumours, non-Müllerian tumours (e.g. lymphomas, soft tissue sarcomas, and adenomas/carcinomas of the thyroid, lung, skin, or breast) were identified in a subset of mice. Lymphomas were the most common non-oviductal tumours (17/80; 21%). Interestingly, three of five mammary carcinomas arose in mice carrying one constitutional inactivated Brca1 allele. The development of lymphomas, sar given the advanced age of many of the mice and the presence of mutant Brca1 and/or Trp53 alleles in the germline of a sizeable subset. In order to determine whether Cre-mediated recombination occurred in the non-Müllerian tumour cells, we evaluated DNA from representative tumours for the presence of recombined Brca1, Trp53, Rb1 and Nf1 alleles (supplementary material, Figure S4 ). We found Cre-mediated recombination of engineered TSG alleles in one endometrial carcinoma (not shown) and in the presumptive thyroid carcinomas, which had morphological features reminiscent of human medullary carcinoma. The remaining tumours appear to have arisen spontaneously. We did not observe OVGP1 expression in the thyroid based on IHC staining, and hence allelic recombination in this site appears to be independent of endogenous Ovgp1 expression. at each of five time points (1, 2, 3, 4 and 6 months after TAM injection). STICs or early HGSC-like lesions were already present in treated mice 1 month after TAM injection. All 10 mice developed bilateral oviductal lesions, including oviductal carcinomas at the later time points. One BPP mouse, examined 6 months after TAM injection, developed carcinosarcoma with metastasis to the ovary and ascites. Endometrial hyperplasia near the junction of the uterine horn with the oviduct was noted in two of the 10 BPP mice. Data from the BPP mice are summarized in supplementary material, Table S3 , and representative photomicrographs of H&E-stained and immunostained lesions arising in the oviducts of BPP mice at 1, 2 and 6 months after TAM injection are shown in Figure 5 . Like tumours arising in BPR, BPRN and BPN mice, oviductal STICs ( Figure 5A, B) , HGSCs ( Figure 5E , F, I, J) and MMMTs ( Figure 5 M, N) arising in BPP mice expressed CK8 ( Figure 5C , G, K, O) and PAX8 ( Figure 5D , H, L, P). As expected, they lacked expression of PTEN, and had an increased Ki67 proliferative index (not shown). In addition, the oviducts of the TAM-treated BPP mice showed rather diffuse epithelial hyperplasia characterized by areas with increased epithelial stratification, as well as mucinous metaplasia (Figure 6 ) in which the cells showed prominent cytoplasmic accumulation of both acidic (Alcian Blue-positive) and neutral (periodic acid-Schiff-positive) mucin as compared with normal oviductal epithelium. These latter findings were not seen in BPR, BPN or BPRN mice. None of the BPP mice developed non-oviductal malignancies during the 6-month surveillance period.
TAM-treated
Discussion
GEMMs that closely mimic the origin, genetics and biological behaviour of HGSC would potentially be of great utility for testing strategies to improve HGSC prevention, early diagnosis, and treatment. Here, we have shown that Ovgp1-iCreER T2 mice carrying conditional mutant TSG alleles relevant to human HGSC pathogenesis develop oviductal STICs, HGSCs and carcinosarcomas that frequently metastasize to the ovaries and/or peritoneum and other organs. Although this is not the first GEMM to target the clinically relevant FTE, it does so with greater specificity than previously described models employing the Pax8 or Amhr2 promoter to direct expression of Cre recombinase in the oviductal epithelium.
We have previously shown that biallelic inactivation of Apc and Pten leads to very different tumour phenotypes when induced in the OSE versus the FTE, with the oviductal tumours closely resembling human endometrioid carcinomas, and the ovarian tumours being more poorly differentiated [22] . In other words, cell of origin plays an important role in determining tumour phenotype. We now show that different combinations of genetic alterations in the FTE also lead to very different tumour phenotypes. In short, whereas genetic alterations (e.g. Apc and Pten inactivation) that dysregulate signalling pathways characteristic of human endometrioid carcinomas result in endometrioid-like tumours in the mouse FTE [22] , mutations commonly seen in human HGSCs result in HGSC-like oviductal tumours. Furthermore, although BPR, BPRN, BPN and BPP mice all develop oviductal STICs and HGSCs/MMMTs following treatment with TAM, the timing of tumour development and progression varies significantly among the different models, and the lesions are not morphologically identical. Specifically, tumour development is very rapid and penetrant in BPP mice, and the FTE acquires diffuse changes (hyperplasia and mucinous metaplasia) not observed in BPR, BPN or BPRN mice. The short latency and rapid disease progression in BPP mice bear some similarity to our prior findings that mice rapidly develop oviductal endometrioid-like carcinomas following biallelic Apc and Pten inactivation by the Ovgp1-iCreER T2 transgene [22] . In BPP and Apc fl/fl ;Pten fl/fl mice, the rapidity of tumour development suggests that the conditional alterations are sufficient for neoplastic transformation of the targeted cells. In contrast, in BPR, BPN and BPRN mice, even those with homozygous floxed alleles for all TSGs, oviductal tumours take longer to develop and progress. Progression from STIC to HGSC/MMMT usually takes well over a year in BPR mice, but is accelerated by addition of biallelic Nf1 inactivation. These findings suggest that tumour initiation and/or progression in BPR, BPN and BPRN mice probably require the acquisition of additional defects, a notion supported by our identification of loss of the wild-type Rb1 alleles in the tumours of mice carrying only one floxed Rb1 allele. The relatively long latency and presumptive need for additional genetic alterations may actually be considered advantageous features of the model system, as the resultant tumour heterogeneity may more closely mimic HGSC pathogenesis in humans than the rapid A potential shortcoming of our model system is the development of non-oviductal tumours in a sizeable proportion of the 80 mice included in the study. This is probably related, at least in part, to the relatively long latency and time required for tumour progression, particularly in BPR and BPN mice. Our data suggest that this problem can be mitigated by focusing future work on TAM-treated BPP or BPRN mice with homozygous floxed alleles (or, in the case of Brca1, Brca1 fl/del alleles), which usually acquire STICs, HGSCs/MMMTs and metastatic disease before they develop non-oviductal tumours that necessitate early euthanasia.
Although the specific cell of origin of HGSC in humans remains unclear, our findings indicate that a population of Ovgp1-expressing cells in the oviduct is susceptible to transformation by somatic mutations akin to those commonly observed in human HGSCs. The transformed cells retain the capacity to differentiate along multiple Müllerian sublineages, both epithelial and mesenchymal. Notably, in contrast to the (Amhr2) Dicer-Pten double-knockout mice described by Kim et al., in which tumours initially arise in the oviductal stroma [17] , the first recognizable lesions in our models are in the FTE. We have previously shown that, like PAX8, OVGP1 is expressed primarily in secretory, rather than ciliated, cells in the mouse FTE [22] . Not surprisingly, transformation of OVGP1-expressing cells results in tumours that express PAX8, a marker of secretory cells, but not tubulin, which is expressed by ciliated cells. The mucinous differentiation of oviductal epithelium noted in TAM-treated BPP mice was not seen in BPR, BPN or BPRN mice, suggesting a role for Pten inactivation in driving this metaplastic change. We have also observed squamous differentiation in occasional tumours arising in the context of Brca1, Trp53 and Pten inactivation (not shown). Mucinous and/or squamous differentiation is commonly seen in human endometrioid carcinomas, which have a high frequency of PTEN mutations [27] . We also 24 Y Zhai et al note some differences between the oviductal lesions in our BPP mice and those based on transformation of PAX8-positive, rather than OVGP1-positive, cells [18] . Although both models develop STICs and HGSCs that express PAX8, Perets et al. [18] did not observe carcinosarcomas or note the diffuse epithelial changes in the oviductal epithelium seen in our BPP mice. These differences suggest, but do not prove, that the cells undergoing transformation in the two model systems are not identical. It is also possible that the tumour phenotypes in these two models are influenced by genetic background.
In summary, our GEMMs recapitulate many of the features seen in human HGSCs. The mouse tumours are based on genetic alterations commonly observed in their human tumour counterparts, and arise in the FTE with a predilection for the oviductal equivalent of the human tubal fimbrial epithelium. The histological features and biological behaviour are also similar to those of human HGSC. The models may prove to be particularly useful for studying the early phases of HGSC pathogenesis and the effects of various factors associated with HGSC risk. For example, although women who have had multiple pregnancies or used oral contraceptives are well documented to have a reduced risk of HGSC [28] , the mechanisms by which this occurs remain unclear. Our GEMMs could be used to systematically test the effects of these factors on tumour initiation and progression. Table S1 . PCR primers for genotyping 
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